Cerebral palsy (CP) is among the most common neurological impairment. It is caused by nonprogressive damage or malformation while the brain is developing and can affect individual’s speech, motor skills, vision, memory, muscle actions, and learning abilities.
Crohn’s Disease (CD) is a life-long, progressive disease that impacts both patients’ physical and mental health. Food can be both harming or beneficial to improve disease outcomes.
The gut microbiota plays an important role in immune development during infancy. In cases where breastfeeding is not possible, an infant formula with HMOs and probiotics may help positively influence the gut microbiota.
HMOs are the third most abundant component of human milk. They remain undigested by the host and reach distal parts of the gastrointestinal tract intact where they can serve as prebiotics with potential antimicrobial, antiadhesive, epithelial and immune cell modulatory effects.
The gut microbiome is important in shaping and regulating human immunity. An efficient and well-tolerant immunity is dependent on a symbiotic partnership between the gut microbiome and the immune system.
Human milk oligosaccharides (HMOs) are an abundant group of diverse bioactives that can be generally categorized accordingly to theirs structures into: Non-fucosylated (core), fucosylated, sialylateds.
The more we learn about human milk oligosaccharides (HMOs), the greater the evidence becomes that they are essential for balanced nutrition during infancy.
Professor Nowak-Wegrzyn highlights how HMO research has progressively shown benefits in healthy infants and those with cow’s milk protein allergy (CMPA), specifically relating to two key HMO: 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT).